The future of leukemia care requires investing in people, not just science
Dr. Jabbour writes about why the future of leukemia care requires investing in people, and a fundraising initiative to help students caught in
Leukemia
Acute Lymphoblastic Leukemia
Podcast
For CML, the science is here now access must follow
Jerald Radich, MD, of Fred Hutchinson Cancer Center in Seattle, sits down with Saad Usmani, MD, of Memorial Sloan Kettering Cancer Center in
Multiple Myeloma
New genomic test provides a less invasive option for myeloma diagnosis
A newly launched test offers a less invasive option for patients with suspected multiple myeloma (MM), using blood or bone marrow to identify
News
Society Updates
SOHO announces new half-day CME program, leadership update
As SOHO continues to expand and connect with a growing global community, we remain focused on supporting hematologic oncologists through targeted, high-impact programming
Ambassador Program
Society Updates
1st SOHO Spain debuts in Madrid, bringing together global hematologists
Dr. Garcia-Manero writes about how the first SOHO Spain brought together 400 top international hematologists for its inaugural meeting in Madrid.
Lymphoma
Meeting News
The Twelfth Annual Meeting of the Society of Hematologic Oncology
Video Interviews
Dr. Kriachok on Ukrainian patients navigating both war, blood cancer care
At the onset of the war in Ukraine, many cancer patients faced immense challenges, with some seeking safety abroad or relocating to more
Meeting News
The Twelfth Annual Meeting of the Society of Hematologic Oncology
Video Interviews
Dr. Kantarjian on 40 years of progress in CML care
In this engaging discussion, Dr. Nitin Jain interviews Dr. Hagop Kantarjian, a global pioneer in leukemia care, about groundbreaking advancements in leukemia and
Leukemia
News
FDA approves revumenib for relapsed or refractory acute leukemia with a KMT2A translocation
The US Food and Drug Administration (FDA) has approved revumenib for relapsed or refractory acute leukemia with KMT2A translocation in adult and pediatric patients
Myelodysplastic Syndromes
News
FDA approves luspatercept in adult patients with low-risk MDS
On August 28, 2023, the US Food and Drug Administration (FDA) approved luspatercept-aamt (Reblozyl) as a first-line treatment for anemia in adult patients
Lymphoma
Indolent B-Cell Lymphomas
News
Epcoritamab shows ‘clinically meaningful activity’ in EPCORE NHL primary analysis
Epcoritamab monotherapy showed a “manageable safety profile” and “clinically meaningful activity” in patients with relapsed or refractory follicular lymphoma who had at least